ArticleTranslational lung cancer research2025
Completion lobectomy following segmentectomy for malignant lung tumors: a multi-institutional study of surgical feasibility, oncologic outcomes, and diagnostic challenges (ESSG-02 study).
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Completion lobectomy (CL) is occasionally required after segmentectomy for malignant lung tumors, particularly in cases of local recurrence at the resection margins. However, evidence of its technical feasibility and long-term outcomes remains limited. This study aimed to evaluate the surgical feasibility and oncologic outcomes of CL following segmentectomy for malignant lung tumors in a multi-institutional cohort. Methods: This multi-institutional retrospective study included 18 patients who underwent CL after segmentectomy for malignant lung tumors between 2000 and 2023. The surgical procedures, perioperative outcomes, and long-term survival were evaluated. An exploratory post-hoc analysis was also performed to compare clinical and radiological features of true local recurrence and granuloma. Results: The most common indication for CL, based on preoperative clinical diagnosis, was local recurrence at the segmental resection margin (72.2%). Video-assisted thoracic surgery (VATS) was performed in 27.8% of patients, with no conversions to thoracotomy. Pulmonary artery (PA) injury occurred in 11.1% and postoperative complications in 27.8%, with prolonged air leak being the most common. Perioperative mortality was not observed. On final pathological diagnosis, 50.0% of patients had local recurrence, 27.8% had metachronous primary lung cancer, and 22.2% had granuloma. Among 13 patients clinically diagnosed with local recurrence preoperatively, 3 were ultimately diagnosed with granuloma. The 5-year overall survival (OS) rate after CL for local recurrence was 58.3%, with a median OS of 87.2 months. An exploratory analysis suggested that features such as interval tumor shrinkage and absence of vascular/bronchial involvement may aid in distinguishing recurrence from granuloma. Conclusions: CL after segmentectomy is a feasible and safe procedure when performed with careful planning and may provide encouraging long-term outcomes. Preoperative differentiation between local recurrence and granuloma remains a challenge and requires thorough imaging and tissue confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.